Abstract
Innovation in psychiatric therapeutics has stagnated on a handful of known mechanisms. Psychiatric genome-wide association studies (GWASs) have begun to identify hundreds of genome-wide significant (GWS) loci and characterize complex polygenic architectures. These data have rapidly advanced our understanding of disease etiology but their ability to inform clinical treatment in psychiatry remains largely unexplored. Here, we show that large psychiatric GWASs (schizophrenia, bipolar disorder, major depressive disorder, and substance use disorders) are enriched (OR: 2.776-27.629) for drug targets of current therapeutics used to treat these disorders (e.g., SNRI’s for MDD; antipsychotics for schizophrenia and MDD). The effect sizes of individual loci and the number of variants identified in a study, but not functional annotations of SNPs, drove enrichment. Psychiatric GWAS results may assist in drug repurposing and novel treatment identification.
Competing Interest Statement
Disclosures: Alexander S. Hatoum is listed as inventor on two preliminary patents related to these analyses, T-020521 - "Treatments for multi-drug or broad addiction liability", and T-020507 "Multi-omics algorithm for testing neurological and psychiatric pharmaceutical efficacy".
Funding Statement
ASH receives funding from the National Institute on Alcohol and Alcohol Abuse; Grant number K01 AA030083
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures:. Alexander S. Hatoum is list as an on inventors on two preliminary patents related to these analyses, T-020521 — “Treatments for multi-drug or broad addiction liability”, and T-020507 “Multi-omics algorithm for testing neurological and psychiatric pharmaceutical efficacy”.
Spencer B. Huggett asked to be removed as an author.
Data availability
The MVP summary statistics were obtained via an approved dbGaP application (phs001672.v4.p1). For details on the MVP, see https://www.research.va.gov/mvp/ and Gaziano, J.M. et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 70, 214-23 (2016)). This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by the Veterans Administration (VA) Cooperative Studies Program (CSP) award #G002.
All other data was downloaded through the Psychiatric Genomics Consortium Website (see: https://pgc.unc.edu/for-researchers/download-results/) and is freely available.
FUMA is an online platform and all data used are available through that platform: https://fuma.ctglab.nl/
All code is available through the first authors github: https://github.com/AlexHatoum
